Navigation Links
Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/16/2009

Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.

(See attached Financial Tables)

                            Orchid Cellmark Inc. and Subsidiaries
                       Condensed Consolidated Statements of Operations
               Three months and twelve months ended December 31, 2008 and 2007
                           (In thousands, except per share data)
                                        (Unaudited)

                                  Three months ended         Years ended
                                      December 31,           December 31,
                                   2008        2007        2008        2007
    Revenues:
      Service revenues           $12,961     $14,948     $57,365     $60,048
      Other 
'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Orchid Cellmark to Announce Fourth Quarter and Year-End 2008 Financial Results on March 16, 2009
2. Orchid Cellmark Reports Third Quarter 2008 Financial Results
3. Orchid Cellmark Reports Second Quarter 2008 Financial Results
4. Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31, 2008
5. Orchid Cellmark Reports First Quarter 2008 Financial Results
6. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
7. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
8. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
9. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
10. Orchid Cellmark Reports Third Quarter 2007 Financial Results
11. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... 29, 2014 Catalent Pharma Solutions, ... advanced delivery technologies for pharmaceutical, biologic, and consumer ... R&D Director and US Platform Leader of Pharmaceutical ... Drugs with Lipid-Based Formulations using Soft Capsule Delivery ... the Japan Society of Drug Delivery Systems (30-31 ...
(Date:7/29/2014)... The Affordable Care Act has created a dramatic ... show that over 400 hospitals probably won’t survive this ... that great hospitals use to survive the threat increases ... secret? Debriefing - the simple process of systematically offering ... operational event. Debriefing is a standard procedure in military ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter , MONDAY, ... three years longer than people who don,t run, according to new ... that it appears that you can reap this benefit even if ... 15-year study suggests. "People may not need to run ... an assistant professor of kinesiology at Iowa State University. "I hope ...
(Date:7/29/2014)... Kelly and Zhi Sheng , assistant professors ... recently received a grant from the Commonwealth Health ... effort that may lead to new treatment approaches. , ... , The grant will fund a two-year project to ... the BRCA1 gene. This type of cancer often has ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Running Could Add 3 Years to Your Lifespan 2Health News:Running Could Add 3 Years to Your Lifespan 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2
... Better ... Treatment Options, WASHINGTON, Nov. 2 Today, the ... for interventional cardiology, announced the,launch of Seconds Count, a ... an authoritative resource about cardiovascular disease and,treatment. The program ...
... AMED or the "Company"), one of America,s leading home ... and,Chief Operating Officer, and Dale E. Redman, Chief Financial ... Annual Healthcare Conference in,New York on Tuesday, November 6, ... Eastern time. The audio,presentation will be webcast live and ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... IDM Pharma, Inc.,(Nasdaq: IDMI ) today announced ... mifamurtide (L-MTP-PE) in patients,with lung metastases as a result ... bone tumor that typically affects children and young,adults. The ... is,safe, well-tolerated and exhibited signs of disease control. ...
... Medical,s blood loss detection,device for monitoring venous needle ... available for sale in the United States. The ... the world,s,first such device. Having met Europe,s rigorous ... granted CE approval. With the FDA,s approval,Redsense is ...
... Statement by James Wagoner on the $28 ... Nov. 1 The following is a,statement ... increase in abstinence-only,program funding:, Today, we ... committee report includes the full $28 million,increase ...
Cached Medicine News:Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3Health News:Amedisys to Present at 2007 CIBC Healthcare Conference in New York 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 2Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 4Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 6Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 7Health News:Redsense Medical Receives FDA Approval for Blood Loss Detection Device 2Health News:Redsense Medical Receives FDA Approval for Blood Loss Detection Device 3Health News:Democrats Cave on Sex Education - Again 2
(Date:7/29/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Tuesday, August 5, 2014 ... management will hold a conference call at 8:00 a.m. ... p.m., Beijing Time on August 6, 2014, to discuss ...
(Date:7/29/2014)... 29, 2014 , Next ... development program has commenced , TPM®/Oxycodone Phase ... during Q4 2014 , TPM®/Oxymorphone Phase 2 ... 1H 2015 Australian drug delivery company, Phosphagenics ... transdermal patch programs after its recent announcement of a $19.2 million ...
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first,natural compound to ... on stroke,recovery starting in the acute stage. ... trial to evaluate the efficacy of NeuroAid(TM) in ... with treatment starting within 48 hours of a ...
... 26 Rcadia Medical Imaging, Ltd.,developer of novel ... Food and Drug Administration (FDA) clearance to market,its ... triaging patients for,coronary artery disease (CAD). The new ... human intervention and automatic detection of,pathologies in the ...
Cached Medicine Technology:International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 2International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 3International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 4Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance 2
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
... for screening donors on the PK7200 Automated ... CMV antigen attached to a gelatin particle ... and specificity of the CMV assay as ... respectively. The use of a gelatin particle ...
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
... designed for medium to ... centers and reference laboratories ... antibody screening. It will ... functions including blood group ...
Medicine Products: